NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal

WEST HAVEN, CONNECTICUT --Monday, March 31, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the "2014 Researcher of the Year" by BusinessNewHaven, a business journal, and the New Haven magazine, that serve the state of Connecticut.

The article was published in the February, 2014 issue of BusinessNewHaven, and is reproduced on the Company's website with permission ( BusinessNewHaven recognizes "Healthcare Heroes" in the state of Connecticut every year. The heroes are chosen from all walks of life in various categories. The magazine seeks to recognize individuals particularly for their persistence, perseverance, novel approaches, and potential for impact on the society. The magazines together have a combined circulation of over 40,000 in Connecticut.

"We recognized Dr. Diwan as the Researcher of the Year because we were impressed by his hard work, the ups and downs that he has faced over his long career in making NanoViricides, Inc. happen, and the fact that he did not quit in the face of adversity," said Mitchell Young, Publisher of Second Wind Media Ltd., of which BusinessNewHaven Magazine is a part, adding, "He was selected from several other nominations, because he represents the essence that we seek in a hero."

"We at NanoViricides congratulate Anil for this recognition," said Dr. Eugene Seymour, MD, MPH, CEO of the Company, "adding we all know the hard work and the brilliant technologies that he has brought forth."

"I am very pleased with this recognition," said Dr. Diwan, adding, "There is still a long way ahead and I am committed to bringing our revolutionary technologies to benefit patients."

About NanoViricides
NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200